• Register
  • Login

Iranian Journal of Pharmaceutical Sciences

  • Home
  • Journal Info
    • About the Journal
    • Aims and Scope
    • Editorial Team
    • Indexing & Abstracting
    • Privacy Statement
    • Contact us
  • Issues
    • Current
    • Archives
  • New Submissions
  • Author Guidelines
  • Policies & Process
    • Peer Review
    • Publication Ethics
    • Open Access Policy
    • Plagiarism
    • Retraction Policies
    • Archiving
  • Ethical Considration
Advanced Search
  1. Home
  2. Archives
  3. Vol. 9 No. 2 (2013): IJPS_Volume 9_Issue 2 (2013)
  4. Research/Original Articles

Vol. 9 No. 2 (2013)

April 2013

Lornoxicam Alone and with Selegiline Improves the Neuroprotective Effect and Cognition in Scopolamine Induced Neurodegeneration and Cognitive Impairment in Rats Neuroprotective Effect of Lornoxicam and Selegiline

  • Sainath Reddy K
  • Kaleem A.K
  • Sharvana Bhava B.S
  • Satish P
  • Aravind P
  • Venkateshwarlu E

Iranian Journal of Pharmaceutical Sciences, Vol. 9 No. 2 (2013), 1 April 2013 , Page 87-101
https://doi.org/10.22037/ijps.v9.40906

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Alzheimer is a progressive neurodegenerative disorder in which Oxidative stress plays a major role. The present study was designed to investigate Neuroprotective effect of Lornoxicam, Selegiline and co-administration of both drugs in Scopolamine induced cognitive impairment and neurodegeneration. Scopolamine (1.4mg/kg) was administered intraperitoniallyin male Wistar rats. Rectangular maze performance test was used to assess the memory performance test. Various biochemical parameters such as Catalase, 1, 1-diphenyl-2- picrylhydrazine (DPPH), Thiobarbituric acid reactive substances(TBARS), reduced glutathione(GSH) and acetylcholine esterase (AchE) were also assessed. IntraperitonialScopolamine results marked memory impairment and oxidative damage. Sub-acute treatment with Lornoxicam (1.3mg/kg, p.o) and Selegiline (0.49mg/kg, p.o) and co-administration of these two drugs for 8 days significantly attenuated scopolamine induced oxidative damage and neurodegeneration. Besides, Lornoxicam, Selegiline and co-administration of both significantly reversed Scopolamine administered increase in acetylcholine esterase activity. Present study indicates protective effect of Lornoxicam, Selegiline and co-administration of both drugs against Scopolamine induced cognitive impairment and oxidative damage. The memory enhancing capacity of the drugs was very significant when compared with disease control (P <0.001).

Keywords:
  • Alzheimer
  • AchE
  • DPPH
  • GSH
  • Lornoxicam
  • Scopolamine
  • Selegiline
  • TBARS
  • IJPS_Volume 9_Issue 2_Pages 87-101

How to Cite

Sainath Reddy K, Kaleem A.K, Sharvana Bhava B.S, Satish P, Aravind P, & Venkateshwarlu E. (2013). Lornoxicam Alone and with Selegiline Improves the Neuroprotective Effect and Cognition in Scopolamine Induced Neurodegeneration and Cognitive Impairment in Rats: Neuroprotective Effect of Lornoxicam and Selegiline. Iranian Journal of Pharmaceutical Sciences, 9(2), 87–101. https://doi.org/10.22037/ijps.v9.40906
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

[1] Mayeux R,Stern Y,Epidemiology of Alzheimer Disease.Cold Spring Harb Perspectives in Medicine (2012) 2(8):1-18.
[2] Minghetti L, Cyclooxygenase-2 (COX-2) in Inflammatory and Degenerative Brain Diseases. J NeuropatholExpNeurol ( 2004) 63(9): 901-910.
[3] Hardy J,Selkoe DJ,The Amyloid Hypothesis of Alzheimer’s disease: Progress and Problems on the Road to Therapeutics. American Association for the Advancement of Science (2002) 297(5580): 353-356.
[4] MarkesberyWR,Neuropathologic Alterations in Mild Cognitive Impairment: A Review.J Alzheimer’s Dis (2010)19(1): 221-228.
[5] Nowotny P, KwonJM, Goate AM, Alzheimer Disease.Encyclopedia of life sciences, Introduction article (2001)
[6] Pithadia A, Pathophysiology and pharmacotherapy of Alzheimer's disease. Int J Pharmacol (2008) 6(1): 1-7.
[7] Yan Z, Feng J,Alzheimer’s disease: Interactions between Cholinergic Functions and β- Amyloid. J CurrAlzheimre’s Dis (2004) 43(4): 241-248.
[8]Govardhan P, Sravanthi A, Mamtha T,Neuroprotective Effects of Meloxicam and Selegiline in Scopolamine-Induced Cognitive Impairment and Oxidative Stress.IntJ Alzheimer’sDis (2012) 53(1): 1-8.
[9] Combs CK, Johnson DE, Karlo JE, Cannady SB, Landreth GE,Inflammatory Mechanisms in Alzheimer’s disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγAgonists, Jneurosci ( 2000) 20(2): 558-567.
[10] Turini ME,Dubois RN,Cyclooxygenase-2: A Therapeutic Target.Annu Rev Medi (2002) 53: 35-57.
[11] Sherbiny DAE, Khalifa AE, Attia AS, Din EE, EldensharyE,Hypericumperforatumextract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine.J Pharmacol,Biochem&Behav (2003)76(3): 523-533.
[12] Kumar A, Vashist A , Kumar A, Kalonia A, Mishra A,Potential role of licofelone, minocycline and their combination against chronic fatigue stress induced behavioral, biochemical and mitochondrial alterations in mice.Pharmacol Rep(2012) 64(5): 1105-1115.
[13] Zhao Y, Dou J, Wu T, Aisa AH,Investigating the Antioxidant and Acetylcholinesterase Inhibition activities of Gossypiumherbaceam. Molecule (2013)18(1): 1951-1962.
[14] Deepan VAT, Sahoo S,Dhanaraju MD,Preliminary Phytochemical Screening and Evaluation of In vitro Antioxidant Activity of AnthocephalousCadambaby Using Solvent Extracts. Eur J BiolSci (2013) 5(1): 134-137.
[15] Kumar A, Dogra S, Prakash A, Protective Effect of Naringin, A Citrus Flavonoid, Against Colchicine-Induced Cognitive Dysfunction and Oxidative Damage in Rats. J Med Food (2010) 13(4): 976-984.
[16] Blokland A,Acetylcholine: a neurotransmitter for learning and memory.Brain Res Rev (2006) 21(3): 285-300.
[17] Attrey DP, Singh AK, Naved T, Roy B,Effect of Sebuckthorn Extract on Scopolamine Induced Cognitive Impairment. Ind J ExpBiol (2012) 50(10): 690-695.
[18] Kiray M, Bagriyanik HA, Pekcetin C, Ergur BU and Uysal N,Protective Effects of Deprenyl in Transient Cerebral Ischemia in Rats. Chin J Physiol (2008), 51(5): 275-281.
[19] Grandman M, Bloom JC, Thal LJ,Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs. Aging and Dementia J NeuSci (1998) 53: 255-275.
[20] Sugimoto H, YamnishiY,LimuraY, Kawakami Y,Donepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors. Curr Med Chem ( 2000) 7(3): 300-339.
[21] Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M,Global prevalence of dementia: a Delphi consensus study.Lancet (2005) 366(9503): 2112-2117.
[22] Basak SS,Candan F,Effect of LaurusnobilisL, Essential Oil and its Main Components on α-glucosidase and Reactive Oxygen Species Scavenging Activity.Ira JPharm Res (2013) 12(2):367-379.
[23] Babitha S, Banji D, Banji OJ, Antioxidant and Hepatoprotective effects of flower extract of Millingtoniahortensis Linn. oncarbontetrachloride induced hepatotoxicity. J PharmBioall Science (2012) 4(4):307-312.
  • Abstract Viewed: 301 times
  • IJPS_Volume 9_Issue 2_Pages 87-101 Downloaded: 244 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Developed By

Open Journal Systems

Information

  • For Readers
  • For Authors
  • For Librarians
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Creative Commons License
This journal (and its contents) is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Print ISSN: 1735-2444

Online ISSN: 2252-0457

Powered by OJSPlus